|
Clinical Trials and Observations
Citations 1-10 of 2356 total displayed.
|
Most recent content
(15 May 2008):
|
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents
- Mark A. Crowther and Theodore E. Warkentin
Blood 2008; 111: 4871-4879.
[Abstract]
[Full text]
[PDF]
Development and validation of a predictive model for chemotherapy-associated thrombosis
- Alok A. Khorana, Nicole M. Kuderer, Eva Culakova, Gary H. Lyman, and Charles W. Francis
Blood 2008; 111: 4902-4907.
[Abstract]
[Full text]
[PDF]
Appraisal of immunoglobulin free light chain as a marker of response
- Angela Dispenzieri, Lijun Zhang, Jerry A. Katzmann, Melissa Snyder, Emily Blood, Roberta DeGoey, Kimberly Henderson, Robert A. Kyle, Martin M. Oken, Arthur R. Bradwell, and Philip R. Greipp
Blood 2008; 111: 4908-4915.
[Abstract]
[Full text]
[PDF]
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century
- Hermann Brenner, Adam Gondos, and Dianne Pulte
Blood 2008; 111: 4916-4921.
[Abstract]
[Full text]
[PDF]
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
- Jean-Jacques Kiladjian, Francisco Cervantes, Franck W. G. Leebeek, Christophe Marzac, Bruno Cassinat, Sylvie Chevret, Dominique Cazals-Hatem, Aurélie Plessier, Juan-Carlos Garcia-Pagan, Sarwa Darwish Murad, Sebastian Raffa, Harry L. A. Janssen, Claude Gardin, Sophie Cereja, Carole Tonetti, Stéphane Giraudier, Bertrand Condat, Nicole Casadevall, Pierre Fenaux, and Dominique C. Valla
Blood 2008; 111: 4922-4929.
[Abstract]
[Full text]
[PDF]
Structural and numerical variation of FLT3/ITD in pediatric AML
- Soheil Meshinchi, Derek L. Stirewalt, Todd A. Alonzo, Titus J. Boggon, Robert B. Gerbing, Jennifer L. Rocnik, Beverly J. Lange, D. Gary Gilliland, and Jerald P. Radich
Blood 2008; 111: 4930-4933.
[Abstract]
[Full text]
[PDF]
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)
- Sandra L. Haberichter, Giancarlo Castaman, Ulrich Budde, Ian Peake, Anne Goodeve, Francesco Rodeghiero, Augusto B. Federici, Javier Batlle, Dominique Meyer, Claudine Mazurier, Jenny Goudemand, Jeroen Eikenboom, Reinhard Schneppenheim, Jorgen Ingerslev, Zdena Vorlova, David Habart, Lars Holmberg, Stefan Lethagen, John Pasi, Frank G. H. Hill, and Robert R. Montgomery
Blood 2008; 111: 4979-4985.
[Abstract]
[Full text]
[PDF]
Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia
- Nicholas B. Heaney, Mhairi Copland, Karen Stewart, Judith Godden, Anne N. Parker, I. Grant McQuaker, Graeme M. Smith, Charles Crawley, Pat Shepherd, and Tessa L. Holyoake
Blood 2008; 111: 5252-5255.
[Abstract]
[Full text]
[PDF]
|
Past content
(since May 1998):
|
Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis
- Marnie J. Wood, Lawrie W. Powell, and Grant A. Ramm
Blood 2008; 111: 4456-4462.
[Abstract]
[Full text]
[PDF]
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
- Nathalie Mourad, Nicolas Mounier, Josette Brière, Emmanuel Raffoux, Alain Delmer, Alfred Feller, Chris J. L. M. Meijer, Jean-François Emile, Réda Bouabdallah, André Bosly, Jacques Diebold, Corinne Haioun, Bertrand Coiffier, Christian Gisselbrecht, and Philippe Gaulard
Blood 2008; 111: 4463-4470.
[Abstract]
[Full text]
[PDF]
|
|
